• Explore /
  • Poster
  • / <span>Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.</span>

Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.

Abstract Poster

Authors

null

Manabu Muto

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Manabu Muto , Motoo Nomura , Katsuyuki Sakanaka , Juko Shimizu , Shinya Ohashi , Akinori Watanabe , Chikatoshi Katada , Yusuke Amanuma , Keiko Minashi , Ken Kato , Takashi Kojima , Kengo Nagashima , Ihhwa Kim , Harue Tada , Akiyoshi Nakakura , Hiroki Sasaki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Local-Regional Disease

Clinical Trial Registration Number

jRCT1091220408

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4068)

DOI

10.1200/JCO.2024.42.16_suppl.4068

Abstract #

4068

Poster Bd #

48

Abstract Disclosures

Similar Posters

First Author: Satoru Matsuda

First Author: Takako Yoshii

First Author: Shun Yamamoto

Poster

2022 ASCO Annual Meeting

Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.

Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.

First Author: Manuel Rodrigues